Abstract: Disclosed is a chiral, total synthesis of thienamycin from D-glucose, which proceeds via intermediates I, II, and III and joins aldehyde IV or acid V, which are known to be useful in the total synthesis of thienamycin (VI): ##STR1## wherein R.sup.1 is hydrogen or a removable protecting group;R is lower alkyl having 1-6 carbon atoms or bi-valent alkyl having 2-6 carbon atoms which joins the two sulfur atoms.

Abstract: Immunologically active compounds of the formula: ##STR1## wherein R.sub.1 is C.sub.1-7 alkyl, substituted C.sub.1-7 alkyl; phenyl; or substituted phenyl;R.sub.2 is hydrogen; or C.sub.1-10 alkyl;R.sub.3 and R.sub.4 may be the same or different and are each independently hydrogen or acyl of the formula: ##STR2## where X is --O--, --S--, --CH.sub.2 --, or ##STR3## R.sub.9, R.sub.10 and R.sub.12 may be the same or different and are each independently hydrogen; C.sub.1-20 alkyl; C.sub.2-20 alkenyl; C.sub.1-20 alkylcarbonyloxy; amino; phenyl; benzyl; C.sub.1-20 alkoxymethyl; or C.sub.1-20 alkylamido;R.sub.11 is hydrogen; C.sub.1-30 alkyl; C.sub.2-30 alkenyl; C.sub.1-30 alkoxy; phenyl; C.sub.1-20 alkylsulfonyl; or cholesteryl; andm is 0-90; and n is 0 or 1, provided that when n is 0, R.sub.

Abstract: Immunologically active compounds of the formula: ##STR1## wherein R.sub.1 is C.sub.1-7 alkyl, substituted C.sub.1-7 alkyl; phenyl; or substituted phenyl;R.sub.2 is hydrogen; or C.sub.1-10 alkyl;R.sub.3 and R.sub.4 may be the same or different and are each independently acyl of the formula: ##STR2## where X is --O--, --S--, or ##STR3## R.sub.9, R.sub.10 and R.sub.12 may be the same or different and are each independently hydrogen; C.sub.1-20 alkyl; C.sub.1-20 alkylcarbonyloxy; amino; benzyl; C.sub.1-20 alkoxymethyl; or C.sub.1-20 alkylamido;r is 0 or 1; s is 0 or 1; and t is 0-20, provided that s may only be 0 when r and t are greater than 0, or when r is 0 and R.sub.11 is amino, phenyl, substituted phenyl, 1-adamantyl, or heterocycle selected from the group consisting of 2- or 3-furyl, 2- or 3-thienyl, 2- or 3-pyrrolidinyl, 2-, 3-, or 4-pyridyl, and 1-tetrazolyl, said hetero-cycle optionally substituted with C.sub.1-20 alkylcarbonyl; andR.sub.11 is hydrogen; C.sub.1-30 alkyl; C.sub.2-30 alkenyl; C.sub.

Abstract: 2-Amino-2-deoxy-glycoses of the general structural formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl (1-7C), substituted alkyl (1-7C), phenyl, substituted phenyl, benzyl, or substituted benzyl;R.sub.2 is alkyl, substituted alkyl, phenyl, or substituted phenyl;R.sub.3 is H or lower alkyl (1-10C) with the proviso that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, R.sub.3 cannot be H;R.sub.4 and R.sub.5 are same or different and are H, aliphatic or aromatic acyl (2-21C) or substituted acyl (2-21C);R.sub.6 is H, or R.sub.6 -R.sub.7 together is --CH.sub.2 --CH.sub.2 --CH.sub.2 --,R.sub.7 is H, alkyl (1-7C), hydroxymethyl, mercaptomethyl, benzyl, or substituted benzyl;R.sub.8 and R.sub.9 each is carboxyl, esterified carboxyl (1-7C), amidated carboxyl, or mono- or di-alkyl-(1-3C)-amidated carboxyl;Provided that when R.sub.

Abstract: The invention disclosed herein relates to novel 1-deoxy-glycopyranosides, preferably 1-deoxy-D-mannopyranosides, having in the 1-position of the pyranoside ring an .omega.-aminoalkylthio, .omega.-aminoalkyloxy or .omega.-aminoalkanoylamino substituent; and to novel processes for preparing these 1-substituted-1-deoxy-glycopyranosides starting with the corresponding tetra-O-acetyl-glycopyranosyl bromide or amine. These .omega.-amino(alkylthio, alkyloxy or alkanoylamino)-1-deoxy-glycopyranosides, and in particular 1-[(6'-aminohexyl)thio or oxy]-1-deoxy-D-mannopyranosides, possess insulin-like activity.